Significance of initial clinical laboratory parameters as prognostic factors in patients with COVID-19

  • Biljana Popovska Jovičić University of Kragujevac, Faculty of Medical Sciences, Department of Infectious Diseases
  • Ivana Raković University of Kragujevac, Faculty of Medical Sciences, Department of Infectious Diseases
  • Aleksandar Pavković University Clinical Center Kragujevac, Department of Radiological Diagnostics
  • Vladan Marković University Clinical Center Kragujevac, Department of Radiological Diagnostics
  • Sara Petrović University of Kragujevac, Faculty of Medical Sciences, Department of Infectious Diseases
  • Jagoda Gavrilović University of Kragujevac, Faculty of Medical Sciences, Department of Infectious Diseases
  • Predrag Čanović University of Kragujevac, Faculty of Medical Sciences, Department of Infectious Diseases
  • Ružica Radojević Marjanović University Clinical Center Kragujevac, Clinic for Infectious Diseases
  • Marko Folić University Clinical Center Kragujevac, Department of Clinical Pharmacology
DOI: https://doi.org/10.2298/VSP220420070P
Ključne reči: biomarkers, body mass index, covid-19, death, disease progression, hematologic tests, prognosis, sars-cov-2, severity of illness index, treatment outcome

Sažetak


Uvod/Cilj. Bolest koronavirus 2019 (COVID-19) je dominantno respiratorna bolest koju izaziva severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Cilj rada bio je da se utvrdi postojanje parametara koji bi mogli da predvide razvoj teške kliničke slike i smrtni ishod kod obolelih od COVID-19. Metode. Istraživanjem su bila obuhvaćena 632 bolesnika lečena na Klinici za infektivne bolesti Univerzitetskog kliničkog centra Kragujevac, u periodu od juna 2020. godine do februara 2021. godine. Svi bolesnici su bili podeljeni u dve grupe na osnovu potrebe za kiseoničnom terapijom (Sat 02 < 94%) Rezultati. Visok indeks telesne mase izdvojio se kao faktor rizika od razvoja teške kliničke slike (ORadjusted = 1,263; 95% CI = 1,117 - 1,427; p < 0,001). Prognostički značaj za razvoj teške kliničke slike imalo je i protrombinsko vreme (ORadjusted = 1,170; 95% CI = 1,004 – 1,364; p = 0,045), kao i niske vrednosti albumina (ORadjusted = 0,878; 95% CI = 0,804 – 0,958; p = 0,003). Faktori koji su imali prognostički značaj kod bolesnika čija se bolest završila smrtnim ishodom bili su C-reaktivni protein (CRP) (ORadjusted = 1,010; 95% CI = 1,001 – 1,019; p = 0,031), laktat dehidrogenaza (LDH) (ORadjusted = 1,004; 95% CI = 1,001 – 1,006; p = 0,002) i radiografski nalaz pluća (ORadjusted = 1,394; 95% CI = 1,170 – 1,661; p < 0,001). Zaključak. Istraživanje je pokazalo da rutinski, kliničko-laboratorijski parametri mogu imati značaj u ranom otkrivanju obolelih sa potencijalno teškom
kliničkom slikom i smrtnim ishodom. Kod obolelih sa lakom kliničkom slikom, CRP, LDH, feritin i nivo albumina u serumu mogu blagovremeno ukazati na progresiju bolesti. Praćenje ovih parametara je od velikog značaja za pravovremenu kliničku procenu stanja obolelih od COVID-19, a samim tim i pravovremenu primenu adekvatnih terapijskih protokola za lečenje tih bolesnika.

Reference

Dhar Chowdhury S, Oommen AM. Epidemiology of COVID-19. J Dig Endosc 2020; 11(1): 3–7.

Liu J, Xie W, Wang Y, Xiong Y, Chen S, Han J, et al. A com-parative overview of COVID-19, MERS and SARS: Review article. Int J Surg 2020; 81: 1‒8.

Subbarao K, Mahanty S. Respiratory virus infections: under-standing COVID-19. Immunity 2020; 52(6): 905‒9.

Hu Z, Song C, Xu C, Jin G, Chen Y, Xu X, et al. Clinical char-acteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. Sci China Life Sci 2020; 63(5): 706‒11.

Kim SE, Jeong HS, Yu Y, Shin SU, Kim S, Oh TH, et al. Viral kinetics of SARS-CoV-2 in asymptomatic carriers and pre-symptomatic patients. Int J Infect Dis 2020; 95: 441‒3.

Barboza JJ, Chambergo-Michilot D, Velasquez-Sotomayor M, Silva-Rengifo C, Diaz-Arocutipa C, Caballero-Alvarado J, et al. Assess-ment and management of asymptomatic COVID-19 infection: A systematic review. Travel Med Infect Dis 2021; 41: 102058.

Qu J, Chang LK, Tang X, Du Y, Yang X, Liu X, Han P, Xue Y. Clinical characteristics of COVID-19 and its comparison with influenza pneumonia. Acta Clin Belg 2020; 75(5): 348‒56.

Maguire D, Woods M, Richards C, Dolan R, Veitch JW, Sim WMJ, et al. Prognostic factors in patients admitted to an ur-ban teaching hospital with COVID-19 infection. J Transl Med 2020; 18(1): 354.

de Bruin S, Bos LD, van Roon MA, Tuip-de Boer AM, Schuurman AR, Koel-Simmelinck MJA, et al. Amsterdam UMC COVID-19 Biobank Investigators. Clinical features and prognostic factors in Covid-19: A prospective cohort study. EBioMedicine 2021; 67: 103378.

Borghesi A, Maroldi R. COVID-19 outbreak in Italy: experi-mental chest X-ray scoring system for quantifying and moni-toring disease progression. Radiol Med 2020; 125(5): 509‒13.

Sun Y, Dong Y, Wang L, Xie H, Li B, Chang C, Wang FS. Characteristics and prognostic factors of disease severity in pa-tients with COVID-19: The Beijing experience. J Autoimmun 2020; 112: 102473.

Gao M, Piernas C, Astbury NM, Hippisley-Cox J, O'Rahilly S, Aveyard P, et al. Associations between body-mass index and COVID-19 severity in 6·9 million people in England: a pro-spective, community-based, cohort study. Lancet Diabetes Endocrinol 2021; 9(6): 350‒9.

Dietz W, Santos-Burgoa C. Obesity and its Implications for COVID-19 Mortality. Obesity (Silver Spring) 2020; 28(6): 1005.

Gao F, Zheng KI, Wang XB, Sun QF, Pan KH, Wang TY, et al. Obesity Is a Risk Factor for Greater COVID-19 Severity. Di-abetes Care 2020; 43(7): e72‒e74.

Hussain A, Mahawar K, Xia Z, Yang W, El-Hasani S. Obesity and mortality of COVID-19. Meta-analysis. Obes Res Clin Pract 2020; 14(4): 295‒300.

Sisó-Almirall A, Kostov B, Mas-Heredia M, Vilanova-Rotllan S, Sequeira-Aymar E, Sans-Corrales M, et al. Prognostic factors in Spanish COVID-19 patients: A case series from Barcelona. PloS One 2020; 15(8): e0237960.

Huang J, Cheng A, Kumar R, Fang Y, Chen G, Zhu Y, et al. Hy-poalbuminemia predicts the outcome of COVID-19 inde-pendent of age and co-morbidity. J Med Virol 2020; 92(10): 2152‒8.

Prins GH, Olinga P. Potential implications of COVID-19 in non-alcoholic fatty liver disease. Liver Int 2020; 40(10): 2568.

Fierro NA. COVID-19 and the liver: What do we know after six months of the pandemic? Ann Hepatol 2020; 19(6): 590‒1.

Luo HC, You CY, Lu SW, Fu YQ. Characteristics of coagula-tion alteration in patients with COVID-19. Ann Hematol 2021; 100(1): 45‒52.

Wang L, He WB, Yu XM, Hu DL, Jiang H. Prolonged pro-thrombin time at admission predicts poor clinical outcome in COVID-19 patients. World J Clin Cases 2020; 8(19): 4370‒9.

Long H, Nie L, Xiang X, Li H, Zhang X, Fu X, et al. D-Dimer and Prothrombin Time Are the Significant Indicators of Se-vere COVID-19 and Poor Prognosis. Biomed Res Int 2020; 2020: 6159720.

Ahnach M, Zbiri S, Nejjari S, Ousti F, Elkettani C. C-reactive protein as an early predictor of COVID-19 severity. J Med Bi-ochem 2020; 39(4): 500‒7.

Herold T, Jurinovic V, Arnreich C, Lipworth BJ, Hellmuth JC, von Bergwelt-Baildon M, et al. Elevated levels of IL-6 and CRP pre-dict the need for mechanical ventilation in COVID-19. J Al-lergy Clin Immunol 2020; 146(1): 128‒36.e4.

Henry BM, Aggarwal G, Wong J, Benoit S, Vikse J, Plebani M, et al. Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: A pooled analysis. Am J Emerg Med 2020; 38(9): 1722‒6.

Chen D, Li X, Song Q, Hu C, Su F, Dai J, et al. Assessment of Hypokalemia and Clinical Characteristics in Patients with Coronavirus Disease 2019 in Wenzhou, China. JAMA Netw Open 2020; 3(6): e2011122.

Alfano G, Ferrari A, Fontana F, Perrone R, Mori G, Ascione E, et al. Hypokalemia in Patients with COVID-19. Clin Exp Neph-rol 2021; 25(4): 401‒9.

Objavljeno
2022/11/01
Broj časopisa
Vol. 79 Br. 09 (2022): Vojnosanitetski pregled
Rubrika
Originalni članak